Given that study has shown that high-dose SGLT-2 inhibitor can further improve LVEF and LVEDD in HFrEF patients compared to standard dose [29], it is necessary to further explore the optimal dosage of dapagliflozin for patients with type 2 diabetes and HFrEF as well as conduct related safety assessments in future research. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.